إجراء مقترح من الاتحاد الأوروبي: المنتجات الكيميائية

This draft Commission Implementing Decision repeals the latest postponement of the expiry date of the approval of magnesium phosphide releasing phosphine as an active substance for use in biocidal products of product-type (PT) 18. On 28 July 2020, an application was submitted in accordance with Article 13(1) of the Regulation (EU) No 528/2012 of the European Parliament and of the Council (BPR) for the renewal of the approval of magnesium phosphide releasing phosphine for PT 18. Commission Implementing Decision (EU) 2021/1285 postponed the expiry date of approval of magnesium phosphide releasing phosphine for PT 18 to 31 July 2024, and Commission Implementing Decision (EU) 2024/787 postponed further the expiry date to 31 January 2026. Finally, the expiry date was again extended, to 31 July 2027, by Commission Implementing Decision (EU) 2025/2284. On 27 May 2026 the Agency adopted its opinion on magnesium phosphide releasing phosphine for PT 18, having regard to the conclusions of the evaluating competent authority. Given the opinion of the Agency, it is appropriate to renew the approval of magnesium phosphide releasing phosphine for PT 18. Consequently, a draft Implementing Regulation is being prepared to renew the approval of magnesium phosphide releasing phosphine for PT 18 (examination procedure under Regulation (EU) No 182/2011). Further to that Implementing Regulation, it is necessary to repeal the latest postponement of the expiry date of the approval of magnesium…